non-alcoholic fatty liver disease

(redirected from Non-alcoholic steatohepatitis)

non-alcoholic fatty liver disease

A fatty liver lacking histologic features typically associated with alcohol abuse, which primarily affects overweight women. With time, patients develop portal changes such as interface hepatitis, increased portal inflammation and fibrosis, and autoantibodies.
 
Risk factors
Diabetes, obesity, hypertension, gallstones, hyperlipidaemia, hypertriglyceridaemia.

Pathogenesis
Uncertain; possibly oxidative stress and lack of antioxidants.

Non-alcoholic fatty liver disease types
• Steatosis;
• Steatosis with inflammation;
• Non-alcoholic steatohepatitis (NASH);
• Cirrhosis.
Mentioned in ?
References in periodicals archive ?
Through its collaboration with Science 37, Novartis had already started virtual trials for cluster headache, acne and non-alcoholic steatohepatitis.
The lead development program is in non-alcoholic steatohepatitis, NASH, with cirrhosis, the most advanced form of NASH related fibrosis.
The end result was non-alcoholic steatohepatitis (Nash) - a dangerous inflammatory condition that can lead to cirrhosis and liver cancer.
Viking"), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive final results from an eight-week study of VK2809 in an in vivo model of non-alcoholic steatohepatitis (NASH).
Promethera hopes the provide a platform to expand the manufacturing capabilities for its liver-derived cell therapies targeting non-alcoholic steatohepatitis (NASH), acute-on-chronic liver-failure (ACLF), and other indications.
Methods: A systematic literature search was performed during March 2016 for randomized controlled trials using PUFA or fish oil supplementation in patients with NAFLD or non-alcoholic steatohepatitis (NASH).
The disease is the consequence of obesity, diabetes, or excessive alcohol intake and can lead to non-alcoholic steatohepatitis (NASH), cirrhosis, liver cancer and even hepatic failure.
com)-- Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis).
Allergan has entered into a definitive agreement to acquire Tobira Pharmaceuticals, a clinical-stage biopharma company developing therapies for non-alcoholic steatohepatitis (NASH) and other liver disease, for a total potential consideration of $1.
The most common risk factor for hepatic steatosis in our cases was alcoholic liver disease and non-alcoholic steatohepatitis.
Long-term pioglitazone is not only safe for patients with non-alcoholic steatohepatitis and prediabetes or type 2 diabetes but may be associated with significant improvements in fatty liver disease outcomes, compared with placebo, a study showed.
The Nimbus Apollo programme includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis, and for the potential treatment of hepatocellular carcinoma and other diseases.

Full browser ?